Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 122

1.

A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells.

Inamoto Y, Flowers ME, Appelbaum FR, Carpenter PA, Deeg HJ, Furlong T, Kiem HP, Mielcarek M, Nash RA, Storb RF, Witherspoon RP, Storer BE, Martin PJ.

Biol Blood Marrow Transplant. 2011 Jul;17(7):1088-92. doi: 10.1016/j.bbmt.2011.01.017. Epub 2011 Mar 21.

2.

Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders.

Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME, Sandmaier BM, Witherspoon RP, Nash RA, Sanders JE, Bedalov A, Hansen JA, Clurman BE, Storb R, Appelbaum FR, Deeg HJ.

Blood. 2007 Aug 15;110(4):1379-87. Epub 2007 May 8.

3.

Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia.

Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE, Greene JE, Linenberger M, Petersdorf E, Sandmaier BM, Scott BL, Sorror M, Stirewalt DL, Stewart FM, Witherspoon RP, Storb R, Appelbaum FR, Deeg HJ.

Biol Blood Marrow Transplant. 2007 Mar;13(3):355-65.

4.

Benchmarks in clinical productivity: a national comprehensive cancer network survey.

Stewart FM, Wasserman RL, Bloomfield CD, Petersdorf S, Witherspoon RP, Appelbaum FR, Ziskind A, McKenna B, Dodson JM, Weeks J, Vaughan WP, Storer B, Perkel S, Waldinger M.

J Oncol Pract. 2007 Jan;3(1):2-8.

5.

Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen.

Deeg HJ, Storer BE, Boeckh M, Martin PJ, McCune JS, Myerson D, Heimfeld S, Flowers ME, Anasetti C, Doney KC, Hansen JA, Kiem HP, Nash RA, O'Donnell PV, Radich JP, Sandmaier BM, Scott BL, Sorror ML, Warren EH, Witherspoon RP, Woolfrey A, Appelbaum FR, Storb R.

Biol Blood Marrow Transplant. 2006 May;12(5):573-84.

6.

A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation.

Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT, Furlong T, Anasetti C, Appelbaum FR, Lloid ME, Deeg HJ, Kiem HP, Martin PJ, Schubert MM, Witherspoon RP, Forman SJ, Blume KG, Storb R.

Biol Blood Marrow Transplant. 2005 Jul;11(7):495-505.

7.

Long-term acquisition of allergen-specific IgE and asthma following allogeneic bone marrow transplantation from allergic donors.

Hallstrand TS, Sprenger JD, Agosti JM, Longton GM, Witherspoon RP, Henderson WR Jr.

Blood. 2004 Nov 15;104(10):3086-90. Epub 2004 Jul 27.

8.

Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation.

Storek J, Dawson MA, Lim LC, Burman BE, Stevens-Ayers T, Viganego F, Herremans MM, Flowers ME, Witherspoon RP, Maloney DG, Boeckh M.

Bone Marrow Transplant. 2004 Feb;33(3):337-46.

PMID:
14647254
9.

Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation.

Chen CS, Boeckh M, Seidel K, Clark JG, Kansu E, Madtes DK, Wagner JL, Witherspoon RP, Anasetti C, Appelbaum FR, Bensinger WI, Deeg HJ, Martin PJ, Sanders JE, Storb R, Storek J, Wade J, Siadak M, Flowers ME, Sullivan KM.

Bone Marrow Transplant. 2003 Sep;32(5):515-22.

PMID:
12942099
10.

Allogeneic hematopoietic stem cell transplantation for myelofibrosis.

Deeg HJ, Gooley TA, Flowers ME, Sale GE, Slattery JT, Anasetti C, Chauncey TR, Doney K, Georges GE, Kiem HP, Martin PJ, Petersdorf EW, Radich J, Sanders JE, Sandmaier BM, Warren EH, Witherspoon RP, Storb R, Appelbaum FR.

Blood. 2003 Dec 1;102(12):3912-8. Epub 2003 Aug 14.

11.

The association between vitamin C and vitamin E supplement use before hematopoietic stem cell transplant and outcomes to two years.

Bruemmer B, Patterson RE, Cheney C, Aker SN, Witherspoon RP.

J Am Diet Assoc. 2003 Aug;103(8):982-90.

PMID:
12891146
12.

Factors affecting antibody levels after allogeneic hematopoietic cell transplantation.

Storek J, Viganego F, Dawson MA, Herremans MM, Boeckh M, Flowers ME, Storer B, Bensinger WI, Witherspoon RP, Maloney DG.

Blood. 2003 Apr 15;101(8):3319-24. Epub 2002 Dec 27.

13.

Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation.

Platzbecker U, Gooley T, Anasetti C, Appelbaum FR, Clurman B, Doney K, Chauncey T, Flowers ME, Myerson D, Radich JP, Storb R, Witherspoon RP, Deeg HJ.

Leuk Lymphoma. 2002 Jul;43(7):1409-14.

PMID:
12389621
14.

Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome.

Deeg HJ, Storer B, Slattery JT, Anasetti C, Doney KC, Hansen JA, Kiem HP, Martin PJ, Petersdorf E, Radich JP, Sanders JE, Shulman HM, Warren EH, Witherspoon RP, Bryant EM, Chauncey TR, Getzendaner L, Storb R, Appelbaum FR.

Blood. 2002 Aug 15;100(4):1201-7.

15.

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.

Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Storb R, Appelbaum FR, Martin PJ.

Blood. 2002 Jul 1;100(1):48-51.

16.

Administration of cyclosporine for 24 months compared with 6 months for prevention of chronic graft-versus-host disease: a prospective randomized clinical trial.

Kansu E, Gooley T, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ.

Blood. 2001 Dec 15;98(13):3868-70.

17.

Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation.

Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, Witherspoon RP, Bensinger W, Flowers ME, Martin P, Storb R, Appelbaum FR, Boeckh M.

Blood. 2001 Jun 1;97(11):3380-9.

18.

Hematopoietic stem-cell transplantation for treatment-related leukemia or myelodysplasia.

Witherspoon RP, Deeg HJ, Storer B, Anasetti C, Storb R, Appelbaum FR.

J Clin Oncol. 2001 Apr 15;19(8):2134-41.

PMID:
11304765
19.

Thalidomide for treatment of patients with chronic graft-versus-host disease.

Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, Sanders JE, Witherspoon RP, Appelbaum FR, Storb R, Martin PJ.

Blood. 2000 Dec 1;96(12):3995-6.

20.

New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.

Socié G, Curtis RE, Deeg HJ, Sobocinski KA, Filipovich AH, Travis LB, Sullivan KM, Rowlings PA, Kingma DW, Banks PM, Travis WD, Witherspoon RP, Sanders J, Jaffe ES, Horowitz MM.

J Clin Oncol. 2000 Jan;18(2):348-57.

PMID:
10637249
21.

Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia.

Witherspoon RP, Deeg HJ.

Haematologica. 1999 Dec;84(12):1085-7.

22.

Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study.

Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ.

Blood. 1999 Oct 1;94(7):2208-16.

23.

Weight loss, skin rash, and cough following bone marrow transplantation for chronic myelogenous leukemia.

Witherspoon RP, McGlave P, Campbell JB, Sigley T, Rolston KV.

Cancer Pract. 1998 Jul-Aug;6(4):202-5. No abstract available.

PMID:
9767331
24.

Long-term outcome after marrow transplantation for severe aplastic anemia.

Deeg HJ, Leisenring W, Storb R, Nims J, Flowers ME, Witherspoon RP, Sanders J, Sullivan KM.

Blood. 1998 May 15;91(10):3637-45.

25.

Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease.

Storek J, Gooley T, Siadak M, Bensinger WI, Maloney DG, Chauncey TR, Flowers M, Sullivan KM, Witherspoon RP, Rowley SD, Hansen JA, Storb R, Appelbaum FR.

Blood. 1997 Dec 15;90(12):4705-9.

26.

IgG response to pneumococcal polysaccharide-protein conjugate appears similar to IgG response to polysaccharide in bone marrow transplant recipients and healthy adults.

Storek J, Mendelman PM, Witherspoon RP, McGregor BA, Storb R.

Clin Infect Dis. 1997 Nov;25(5):1253-5. No abstract available.

PMID:
9402399
27.
28.

Long-term follow-up of allogeneic marrow transplants in patients with aplastic anemia conditioned by cyclophosphamide combined with antithymocyte globulin.

Storb R, Leisenring W, Anasetti C, Appelbaum FR, Buckner CD, Bensinger WI, Chauncey T, Clift RA, Deeg HJ, Doney KC, Flowers ME, Hansen JA, Martin PJ, Sanders JE, Sullivan KM, Witherspoon RP.

Blood. 1997 May 15;89(10):3890-1. No abstract available.

29.

Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.

Deeg HJ, Lin D, Leisenring W, Boeckh M, Anasetti C, Appelbaum FR, Chauncey TR, Doney K, Flowers M, Martin P, Nash R, Schoch G, Sullivan KM, Witherspoon RP, Storb R.

Blood. 1997 May 15;89(10):3880-7.

30.

Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation.

Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Soll E, Anasetti C, Bowden R, Bryant E, Chauncey T, Deeg HJ, Doney KC, Flowers M, Gooley T, Hansen JA, Martin PJ, McDonald GB, Nash R, Petersdorf EW, Sanders JE, Schoch G, Stewart P, Storb R, Sullivan KM, Thomas ED, Witherspoon RP, Appelbaum FR.

Blood. 1997 Apr 15;89(8):3055-60.

31.

Solid cancers after bone marrow transplantation.

Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socíe G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF Jr, Boice JD Jr.

N Engl J Med. 1997 Mar 27;336(13):897-904.

32.

Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts.

Storek J, Gooley T, Witherspoon RP, Sullivan KM, Storb R.

Am J Hematol. 1997 Feb;54(2):131-8.

33.

Reconstitution of membrane IgD- (mIgD-) B cells after marrow transplantation lags behind the reconstitution of mIgD+ B cells.

Storek J, Witherspoon RP, Storb R.

Blood. 1997 Jan 1;89(1):350-1. No abstract available.

34.

Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation.

Martin PJ, Nelson BJ, Appelbaum FR, Anasetti C, Deeg HJ, Hansen JA, McDonald GB, Nash RA, Sullivan KM, Witherspoon RP, Scannon PJ, Friedmann N, Storb R.

Blood. 1996 Aug 1;88(3):824-30.

35.

Lack of B cells precursors in marrow transplant recipients with chronic graft-versus-host disease.

Storek J, Witherspoon RP, Webb D, Storb R.

Am J Hematol. 1996 Jun;52(2):82-9.

36.

Marrow transplantation for hepatitis-associated aplastic anemia: a follow-up of long-term survivors.

Kiem HP, McDonald GB, Myerson D, Spurgeon CL, Deeg HJ, Sanders JE, Doney K, Appelbaum FR, Sullivan KM, Witherspoon RP, Storb R.

Biol Blood Marrow Transplant. 1996 May;2(2):93-9.

PMID:
9118304
37.

A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.

Sullivan KM, Storek J, Kopecky KJ, Jocom J, Longton G, Flowers M, Siadak M, Nims J, Witherspoon RP, Anasetti C, Appelbaum FR, Bowden RA, Buckner CD, Crawford SW, Deeg HJ, Hansen JA, McDonald GB, Sanders JE, Storb R.

Biol Blood Marrow Transplant. 1996 Feb;2(1):44-53.

PMID:
9078354
38.

Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors.

Anderson JE, Appelbaum FR, Schoch G, Gooley T, Anasetti C, Bensinger WI, Bryant E, Buckner CD, Chauncey TR, Clift RA, Doney K, Flowers M, Hansen JA, Martin PJ, Matthews DC, Sanders JE, Shulman H, Sullivan KM, Witherspoon RP, Storb R.

Blood. 1996 Jan 1;87(1):51-8.

39.

Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients.

Deeg HJ, Socié G, Schoch G, Henry-Amar M, Witherspoon RP, Devergie A, Sullivan KM, Gluckman E, Storb R.

Blood. 1996 Jan 1;87(1):386-92.

40.
41.

Low IgG production by mononuclear cells from marrow transplant survivors and from normal neonates is due to a defect of B cells.

Storek J, Witherspoon RP, Luthy D, Storb R.

Bone Marrow Transplant. 1995 May;15(5):679-84.

PMID:
7670395
42.

Secondary malignancies after marrow transplantation for leukemia or aplastic anemia.

Witherspoon RP, Deeg HJ, Storb R.

Transplant Sci. 1994 Sep;4(1):33-41. Review.

PMID:
7804695
43.

Secondary malignancies after marrow transplantation for leukemia or aplastic anemia.

Witherspoon RP, Deeg HJ, Storb R.

Transplantation. 1994 May 27;57(10):1413-8. No abstract available.

PMID:
8197599
44.

Marrow transplant experience for children with severe aplastic anemia.

Sanders JE, Storb R, Anasetti C, Deeg HJ, Doney K, Sullivan KM, Witherspoon RP, Hansen J.

Am J Pediatr Hematol Oncol. 1994 Feb;16(1):43-9.

PMID:
8311172
45.

Long-term survival and cure after marrow transplantation for congenital hypoplastic anaemia (Diamond-Blackfan syndrome).

Greinix HT, Storb R, Sanders JE, Deeg HJ, Doney KC, Sullivan KM, Witherspoon RP.

Br J Haematol. 1993 Jul;84(3):515-20.

PMID:
8217802
46.

Risk factors for the development of secondary malignancies after marrow transplantation.

Deeg HJ, Witherspoon RP.

Hematol Oncol Clin North Am. 1993 Apr;7(2):417-29. Review.

PMID:
8468274
47.

Etoposide, cyclophosphamide and fractionated total body irradiation as a preparative regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.

Petersen FB, Buckner CD, Appelbaum FR, Sanders JE, Bensinger WI, Storb R, Deeg HJ, Witherspoon RP, Sullivan KM, Clift RA, et al.

Bone Marrow Transplant. 1992 Jul;10(1):83-8.

PMID:
1515884
48.

Marrow transplantation for paroxysmal nocturnal hemoglobinuria.

Kawahara K, Witherspoon RP, Storb R.

Am J Hematol. 1992 Apr;39(4):283-8.

PMID:
1553957
49.

Marrow transplantation for Fanconi anemia with or without leukemic transformation: an update of the Seattle experience.

Flowers ME, Doney KC, Storb R, Deeg HJ, Sanders JE, Sullivan KM, Bryant E, Witherspoon RP, Appelbaum FR, Buckner CD, et al.

Bone Marrow Transplant. 1992 Mar;9(3):167-73.

PMID:
1511254
50.

Cumulative incidence of secondary solid malignant tumors in aplastic anemia patients given marrow grafts after conditioning with chemotherapy alone.

Witherspoon RP, Storb R, Pepe M, Longton G, Sullivan KM.

Blood. 1992 Jan 1;79(1):289-91. No abstract available.

Supplemental Content

Loading ...
Support Center